Entity
Description
  • Value proposition

    We are on a mission to develop gene replacement therapy for the CTNNB1 Syndrome.

    CTNNB1 Foundation is leading worldwide gene therapy program

Catalyst interactions
Catalyst TypeTweets Articles
Bayer
Bayer
Chemistry, Pharmaceutical, Chemical Manufacturing
Bayer
Chemistry, Pharmaceutical, Chemical Manufacturing
Other

28 Feb 2025


Social network dynamics
Loading...